During a live event, Thomas G. Martin, MD, discussed the importance of controlling disease and avoiding barriers to access so patients with multiple myeloma can receive CAR T-cell therapy.

Rigel Pharmaceuticals, Inc. posted a solid Q3 with robust sales growth. Discover insights on future profitability and market ...

Discover why Rigel Pharma (RIGL) is a contrarian biotech BUY with surging revenues, strong drug sales, and 20-30% upside ...

Biomarkers such as ring sideroblasts are indicators for response to treatments like luspatercept (Reblozyl). In patients with ...

Systemic therapy is often given late due to optimism bias, treatment momentum, and difficulty in end-of-life conversations, ...

CURE spoke with Dr. Marina Kremyanskaya about the treatment landscape for patients with polycythemia vera.

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute ...

Final 5-year data from the phase 2 2102-HEM-101 trial (NCT02719574) show that olutasidenib (Rezlidhia; Rigel Pharmaceuticals, ...

The two neurodegenerative diseases could not appear more different. Amyotrophic lateral sclerosis (ALS), sometimes called Lou ...

Bristol Myers Squibb today announced the presentation of more than 95 data disclosures, including 27 oral presentations, across company-sponsored studies and external collaborations at the 67th ...

A new study of adolescents and young adults (AYAs) with seven common cancers reveals that nearly one in ten patients ...

Rocket Doctor Inc. CEO Dr. Bill Cherniak was invited to speak at the Google Accelerator Alumni Event in Mexico City, joining a panel of 3 other founders in front of an audience of hundreds of Google ...